Drug combination

Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML

Retrieved on: 
Thursday, November 9, 2023
EHA, CD38, Associate, UCSF Benioff Children's Hospital, European Hematology Association, Juvenile myelomonocytic leukemia, Transplant, Disease, Database, UCSF, Patient, ASCO, Hematopoietic stem cell transplantation, APL, AZA, Blood, Cytarabine, FLA, Cancer, Tretinoin, Acute promyelocytic leukemia, Trial of the century, Malignancy, Society, Physician, Cell, Bone marrow, Drug combination, Pharmaceutical industry, JMML

FOSTER CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced the publication of data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more effective pre-hematopoietic stem cell transplantation (pre-HSCT) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) in the November 9th Issue of the American Society of Clinical Oncology (ASCO) Journal JCO Precision Oncology. Part of this data was recently presented at the European Hematology Association (EHA) Hybrid Congress held in Frankfurt, Germany on June 8 – 15, 2023. Details of that presentation can be found on the Company’s website at https://notablelabs.com/.

Key Points: 
  • JMML is a rare, aggressive pediatric malignancy for which curative treatment is restricted to hematopoietic stem cell transplantation.
  • Pre-HSCT therapies, i.e., therapies prior to transplantation, include moderately intensive chemotherapy (particularly fludarabine and cytarabine in combination (FLA)) and azacytidine (AZA) monotherapy.
  • Applying its proprietary PPMP technology to blood or bone marrow samples from JMML patients, Notable screened 130 drug combinations and discovered that 27 of these combinations (26 dual-, 1 triple-combination) were more effective ex vivo than the components of these combinations tested individually.
  • “This publication marks the culmination of a multi-year collaboration between UCSF and Notable Labs,” remarked Dr. Stieglitz.

Bicycle Therapeutics Provides Data Updates for Three Clinical Programs and Strategy Overview at First R&D Day

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Webcast, MT1-MMP, Peripheral neuropathy, Brain, Safety, Immune system, Cervical cancer, Food, Therapy, Toxicity, Head, Diabetic neuropathy, Nobel Prize, Patient, CD137, Bicycle, FDA, Non-small-cell lung cancer, Pembrolizumab, Neoplasm, Ionis, Investigational New Drug, Brentuximab vedotin, MUC, ORR, Ovary, Anal cancer, Cancer, Ovarian cancer, Toxic leukoencephalopathy, Pain, R, Drug combination, EV, Central nervous system, TNBC, NSCLC, BRC, Pharmaceutical industry, Vaccine, Birth control, Medical imaging, Thromboxane A2

“In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers.

Key Points: 
  • “In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers.
  • BT8009 is a Nectin-4 Bicycle toxin conjugate (BTC®) designed to overcome the significant toxicity associated with other toxin conjugate approaches.
  • Over 2024, Bicycle Therapeutics intends to generate early human imaging data from its wholly owned BRC pipeline.
  • Bicycle Therapeutics will continue to develop Bicycle® molecules to address disease outside of oncology through innovative partnerships.

Foundation Medicine Announces Participation in National Cancer Institute’s ComboMATCH Initiative to Connect Patients with New Anti-Cancer Drug Combinations

Retrieved on: 
Thursday, October 26, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Patient, Combination, NCI, Foundation Medicine, MD, Doctor of Philosophy, National Cancer Institute, Alliance for Clinical Trials in Oncology, Partnership, Cancer, Drug combination, Bangladesh Technical Education Board, Pharmaceutical industry, Nursing, Medical imaging

Foundation Medicine, Inc., today announced its participation in the National Cancer Institute’s (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer.

Key Points: 
  • Foundation Medicine, Inc., today announced its participation in the National Cancer Institute’s (NCI) Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH) initiative to test new therapy combinations in select groups of adults and children with cancer.
  • Foundation Medicine is one of nearly 40 participating Designated Laboratories, meaning that oncologists at participating ComboMATCH clinical sites may utilize their patients' FoundationOne®CDx commercial testing results to help determine their eligibility for ComboMATCH treatment trials.
  • ComboMATCH tests whether therapy selected in this manner to treat cancer may provide better patient outcomes than the current standard of care.
  • Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.

LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration

Retrieved on: 
Monday, October 16, 2023
Cancer, NKI, Research, PP2A, Netherlands Cancer Institute, Drug combination, Immunotherapy, Patient, Pharmaceutical industry

PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers. The new agreement also will seek to find synthetic lethal combinations in additional cancer types.

Key Points: 
  • PASADENA, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW) announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute (NKI) and Oncode Institute to study drug synergies of LIXTE’s lead clinical compound, LB-100, with immunotherapy in various cancers.
  • The new agreement also will seek to find synthetic lethal combinations in additional cancer types.
  • NKI, based in Amsterdam, Netherlands, is among the world’s leading comprehensive cancer centers.
  • Oncode Institute, headquartered in Utrecht, Netherlands, is a major independent cancer research center dedicated to translating research into practice and bringing discoveries into a clinic setting more quickly.

Inflammatory Breast Cancer: Know the Risks and Warning Signs of This Rare, Fast-Growing Cancer

Retrieved on: 
Monday, October 9, 2023
Breast, Woman, IBC, American Cancer Society, Breast cancer, Risk, Disease, Cancer, Drug combination, Immunotherapy, Biopsy, ACS, Infection, MRI, News, Menopause, Skin, Breast MRI, Radiation, Diagnosis, Breast Cancer Awareness Month, Birth control, Medical imaging, Engineered wood

ATLANTA, Oct. 9, 2023 /PRNewswire/ -- Inflammatory breast cancer (IBC) is a rare type of breast cancer. It only accounts for one to five percent of all breast cancer cases, but it's important to know your risk and the warning signs, as this form of the disease is aggressive, fast-growing, and hard to detect early. For October, during Breast Cancer Awareness Month, the American Cancer Society (ACS) is highlighting IBC to help women be aware of this invasive cancer.

Key Points: 
  • ATLANTA, Oct. 9, 2023 /PRNewswire/ -- Inflammatory breast cancer (IBC) is a rare type of breast cancer.
  • It only accounts for one to five percent of all breast cancer cases, but it's important to know your risk and the warning signs, as this form of the disease is aggressive, fast-growing, and hard to detect early.
  • For October, during Breast Cancer Awareness Month, the American Cancer Society (ACS) is highlighting IBC to help women be aware of this invasive cancer.
  • "IBC is tricky as it doesn't usually present with a breast lump like many women expect when they think of a breast cancer.

Aitia and Pancreatic Cancer Action Network Partner to Transform De-Identified Multi-Omic Patient Data into Digital Twins to Drive New Discoveries and Improve Patient Outcomes

Retrieved on: 
Wednesday, September 27, 2023
Pancreatic cancer, Causal AI, Survival, Research, Biomarker, Patient, ACS, Drug combination, American Cancer Society, Digital twin, American Cancer Society Cancer Action Network, Disease, Pharmaceutical industry, SPARK, Causality (physics)

This strategic collaboration marks a significant milestone for Aitia, reinforcing its commitment to expanding its impact and accelerating the discovery and development of new drugs in pancreatic cancer.

Key Points: 
  • This strategic collaboration marks a significant milestone for Aitia, reinforcing its commitment to expanding its impact and accelerating the discovery and development of new drugs in pancreatic cancer.
  • Pancreatic cancer, responsible for over 466,003 global deaths in 2020 according to Global Cancer Statistics , is showing promising progress.
  • The American Cancer Society's (ACS) Cancer Facts & Figures 2023 report reveals an all-time high five-year survival rate of 12% for pancreatic cancer.
  • "Our collaboration with Aitia opens new doors to cutting-edge research and development, offering hope to pancreatic cancer patients and their families.

Navigate BioPharma Services, Inc. Announces Collaboration with BD (Becton, Dickinson and Company) to Advance Capabilities for Clinical Phases of Drug Development

Retrieved on: 
Thursday, September 7, 2023
Business development, Workflow, Biotechnology, Clinical trial, Cancer, Multimedia, Biomarker, Biopharma LLC, MRD, Becton, Dickinson and Company headquarters, Novartis, Patient, Automation, Drug combination, Flow cytometry, IVD, Becton, Navigation, Safety, BDX, NYSE, BD, Software, Medical device, Medical imaging, Mobile phone

Importantly, this collaboration aims to address a critical gap in the clinical trial field for an integrated solution provider from method development to commercialization.

Key Points: 
  • Importantly, this collaboration aims to address a critical gap in the clinical trial field for an integrated solution provider from method development to commercialization.
  • Vipin Bhambhani, VP of Clinical Flow Solutions, BD Biosciences said, "Flow cytometry is a powerful technique that can enable high-sensitivity, affordable testing with fast turnaround time.
  • Providing flexible and integrated solutions that can help collaborators achieve their clinical and regulatory goals by leveraging the capabilities of flow cytometry.
  • Over the past decade, Navigate BioPharma has built and developed its exclusive library of assays, methodologies, and biomarker solutions.

Elastin Biosciences Announces Breakthrough Discovery in Elastin Restoration: Paving the Way for Treatment of Elastin-Deficiency Diseases

Retrieved on: 
Friday, September 1, 2023
Biotechnology, Health, General Health, Seniors, Pharmaceutical, Other Science, Alternative Energy, Energy, Consumer, Science, Clinical Trials, University, Elastin, Ageing, Research, Regenerative medicine, Organization, Radar, Drug combination, Mouse, Longevity, Pharmaceutical industry

Longaevus Technologies, announces the spin-off of Elastin Biosciences following breakthrough preclinical results of 3 of its assets.

Key Points: 
  • Longaevus Technologies, announces the spin-off of Elastin Biosciences following breakthrough preclinical results of 3 of its assets.
  • After being in stealth mode for a year, Elastin Biosciences, an innovative biotech company spun off from Longaeuvus Technologies, has unveiled a groundbreaking discovery in the realm of elastin-related health.
  • In a testament to the importance and potential of this research, Elastin Biosciences has secured an initial funding of $2.5 million.
  • Elastin Biosciences is now poised to make significant strides in regenerative medicine, ushering in a new era of treatment solutions and healthy aging.

Burning Rock Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 31, 2023
LSE, The New England Journal of Medicine, Science Translational Medicine, Water Drops on Burning Rocks, Progression-free survival, Marketing, NGS, Fulvestrant, Breast, Research, ID, Precision, AstraZeneca, Liver cancer, ASCO, HR, US, Hospital, Patient, Organoid, Investment, Drug combination, Webcast, Depreciation, CDX, Ovarian cancer, Safety, Disease, Pharmaceutical industry, Fine chemical, Cryptocurrency

GUANGZHOU, China, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2023.

Key Points: 
  • GUANGZHOU, China, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2023.
  • Presented study results on extensive-stage small-cell lung cancer and ovarian cancer at the ASCO in June 2023.
  • Results of the study “Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology” were published at the Science Translational Medicine in August 2023.
  • Burning Rock will host a conference call to discuss the second quarter 2023 financial results at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on August 31, 2023.

Personalized Pharmaceuticals: Global 3D Printed Drugs Market to Reach USD 157.46 Million by 2028

Retrieved on: 
Wednesday, August 30, 2023
3D, USD, COVID-19, Patient, Nature, Drug combination, Geography, Drug discovery, Quality control, API, Health, Safety, 3D printing

The Global 3D Printed Drugs Market is estimated to be USD 74.04 Mn in 2023 and is expected to reach USD 157.46 Mn by 2028, growing at a CAGR of 16.29%.

Key Points: 
  • The Global 3D Printed Drugs Market is estimated to be USD 74.04 Mn in 2023 and is expected to reach USD 157.46 Mn by 2028, growing at a CAGR of 16.29%.
  • Constant technological advances in 3D printing processes create considerable prospects in the market for 3D printed drugs.
  • The increase in healthcare investment in emerging markets gives the potential for the 3D printed drugs market to flourish.
  • The presence of severe government rules for 3D printed drugs is a major market challenge in the 3D printed pharmaceuticals business.